The UW/FHCRC Center for AIDS Research (CFAR) announces the availability of administrative supplement funding from the NIH CFAR Program for projects related to the below areas of scientific interest. Funding available per project is a maximum of $100,000 direct costs for one year.
Scientific Areas of Interest (further details are included in the NIH Supplement Announcement and linked to below):
Project leaders are restricted to either
- Early Stage Investigators – those who have not yet previously competed successfully as a PI for a substantial NIH independent research award and who are within 10 years of completing their terminal research degree or medical residency at the time they apply. For more information, please see the NIH definition of new and early stage investigator .
- Established investigators in non-HIV fields who have never received an NIH research award for HIV/AIDS studies.
Mentorship and collaboration with established AIDS investigators is required. CFAR Core and Scientific Working Group leaders are encouraged to collaborate on their applications, and to collaborate with appropriate individuals not currently involved in AIDS research.
Studies involving clinical trials are not allowed. If your proposed study design involves testing a biomedical or behavioral intervention, please contact Lauren Sterling (firstname.lastname@example.org ) to check allowability.
Studies that are an expansion of previously funded CFAR supplements or funded NIH applications that do not address new specific aims are not eligible for funding under this announcement. Awards will be made as supplements to the UW/FHCRC CFAR grant.
Concept Sheet Instructions
Each CFAR is limited to submitting a maximum of one application per scientific area of interest; therefore we are conducting an internal competition to determine which applications will go forward for submission to the NIH. To apply for this opportunity, please do the following:
1. Email Lauren Sterling (email@example.com ) a non-binding “email of intent” listing proposed Project Director, Title, Mentor(s) (if applicable), and names of collaborators. Please also include names and contact information of at least two non-conflicted reviewers for your proposal. Also indicate whether your proposed project would involve a foreign component and specify the location. DEADLINE: Thursday, April 9, 2015, 3pm PDT.
2. Submit a concept proposal by COB Monday, April 13, 2015 5pm PDT, which includes the following:
A. Cover letter with title of proposed project (maximum of 81 characters), name and contact information of Project Director, and name(s) and contact information of Mentor(s), if applicable.
Please also address the following:
1) Identify which of the areas listed in the bulleted section of the full announcement that you are applying toward.
2) Please note whether you will be proposing an international component and specify the location.
3) Include a table listing the key personnel to participate in the proposed project, including the following information: Names, degrees, institutional affiliations, and roles in project.
4) Include a brief description of how you have addressed the purpose of this opportunity and the eligibility requirements described in the announcement. Please review the entire full announcement  to ensure you are addressing all eligibility requirements.
B. Description of proposal (limit one page, Arial 11 font or equivalent)
Briefly address the following:
1) Background and rationale for the proposal
2) Activities to be undertaken
3) Expected outcome of these activities (value-added)
4) Expected follow-up plan upon completion of the project
5) A description of how the supplement and follow-up plan are expected to achieve this outcome
Most importantly, clearly indicate how the proposed research activities are expected to lead to the development of stated goals.
Applicants are strongly encouraged to review the review criteria listed in the full announcement.
C. NIH-formatted Biosketch  of Project Director. Please make sure to include past and current Research Support so that we can confirm Project Director eligibility.
D. Brief description of budget by cost category (salaries, benefits, supplies, equipment, travel, other services, subcontracts). Be sure that the aims of the proposal can be achieved with the given budget. Refer to the NIH Grants Policy Statement regarding allowable and unallowable costs. Please note that subcontract indirect costs are allowable. Contact Lauren Sterling (firstname.lastname@example.org ) if you have any questions regarding the budget.
SUBMIT CONCEPT PROPOSALS ELECTRONICALLY IN ONE FILE (MS Word or Adobe PDF) TO LAUREN STERLING (email@example.com ) BY 5pm PDT, Monday, April 13, 2015.
After selection of the finalists, full proposals (research plan can be in draft form; budget must be final) are due by Tuesday, May 12, 2015, and research plan must be final by Monday, May 18, 2015.
Questions may be directed to Lauren Sterling (206-744-8876; firstname.lastname@example.org ).
Additional Information on Scientific Areas of Interest
Oral HIV antiretroviral pre-exposure prophylaxis (PrEP) confers a strong preventive benefit to individuals who are at-risk for HIV infection when taken with high adherence. PrEP uptake has been slow, and research is needed to better understand the multi-level factors that may influence PrEP uptake and effective use.
Formative research is encouraged to inform better targeting, engagement, and retention of the highest-risk populations in PrEP care. Novel approaches designed to identify appropriate individuals for PrEP and improve understandings of risk perceptions and decision-making could improve PrEP uptake. Models for retention of individuals in all facets of PrEP care will need to be explored in a variety of potential settings. Effective support for adherence and persistence are also critical to maximizing the preventive benefits of oral PrEP.
Responsive studies could include, but are not limited to the following:
- Mixed-methods studies to better understand the multi-level factors that may influence selection of PrEP as a prevention option
- Developmental work to inform communication strategies to promote engagement in PrEP programs and PrEP uptake
- Pilot studies on novel approaches to reach high-risk individuals and link them to PrEP care
- Research to develop and pilot test interventions promoting retention of high-risk groups in PrEP care
- Research to develop and pilot test interventions designed to improve and sustain adherence to oral PrEP
- Studies designed to characterize rates, patterns, and determinants of PrEP uptake, adherence, and persistence under open-label use
- Research examining patterns of PrEP adherence in relationship to patterns of risk behavior.
There is significant diversity in the levels of HIV prevalence and incidence between and within geographical regions, and even greater diversity when populations are stratified by age, sex, ethnicity, and high risk behaviors. These variations suggest that identifying and focusing on particular high-incidence locations and populations could lead to greater gains in preventing new infections. Furthermore, assessments of viral phylogenetics within these microepidemics have the potential to expand the specificity of HIV transmission dynamics within populations. More detailed knowledge of HIV transmission networks will be important in tailoring the design, implementation and assessment of public health, therapeutic, and behavioral interventions.
The scientific objective of this supplement is to stimulate cross-disciplinary collaborations to identify and target the key microepidemics within high prevalence areas, with the overarching goal to lower HIV prevalence and incidence. Because considerable data are collected in the research and public health spheres, investigators are encouraged to work with their relevant public health agencies to expand the breadth of data available on their local epidemic.
Responsive studies could include, but are not limited to the following:
- Molecular/viral phylogenetics of transmission networks, particularly where data from research can be combined with data collected by relevant public health agencies
- Geospatial mapping
- Identifying transmission dynamics and/or HIV transmission network characteristics. Examples include temporal, spatial, and behavioral dynamics
- Exploring transmission networks in combination with detailed clinical, epidemiological, and behavioral data.
The CFAR program has several inter-CFAR collaborations with different names (e.g. working group, network, and consortium) that profess to the importance of cross collaborations across different CFARs. The goal of this topic is to request research projects that can be clearly identified as value added to the CFAR program. Below is a list of existing inter-CFAR collaborations that are eligible to apply for a supplement under this topic. Applications must propose a research project that is within the scope of the eligible groups.
- CFAR HIV Continuum of Care Working Group
- CFAR Network of Integrated Clinical Systems (CNICS)
- CFAR Social and Behavioral Sciences Research Network (SBSRN)
- Inter-CFAR HIV/AIDS Related Malignancy (iCHARM) Working Group
- Inter-CFAR Collaboration on HIV Research in Women
- CFAR Global AIDS Research Consortium (CGARC)
- CFAR HIV/TB Co-Infection Consortium
- CFAR–CFAR Collaboration on HIV in Corrections (CFAR–CHIC)
- CFAR Biostatistics Network
- CFAR Sub-Saharan Africa Working Group
- Inter-CFAR Cytometry Interest Group (CIG)
- HIV and Aging Inter-CFAR Working Group
The idea behind this supplement topic is to request supplements from members of these inter-CFAR collaborations that support some research project that will provide value added to the inter-CFAR group and build on ongoing group collaborations. The proposed work has to include investigators from at least two or more CFARs that are members of the group. The supplement should be driven by a research project. For example, the iCHARM Working Group may submit a supplement where two or more iCHARM members propose a research project in cancer that brings together different expertise from the different members. The CFAR Biostatistics Network can submit a supplement that proposes novel biostatistical methods. The CFAR–CFAR Collaboration on HIV in Corrections could propose a project focused on barriers to HIV care or mental health services issues for people in jail or recently released.
Each supplement request requires that investigators from at least two different CFARs be involved in the supplement application. The team would have to decide which investigator at one of the participating CFARs would be the lead PI and thus the submitting CFAR; all other inter-CFAR investigators would be key personnel. In addition to a research plan, the supplement application requires a section where the investigators describe how this supplement will add value to the inter-CFAR collaboration and how it will serve as catalyst to more productive inter-CFAR collaborations. The supplement must also describe the role of each inter-CFAR member on the project.
This topic cannot be used to propose support for a meeting, conference, mentoring session or working group meeting. This supplement will not allow travel unless highly justified as critical to the success of the project. Project leaders for this topic also must be early stage investigators or investigators new to HIV. One application per CFAR will be allowed.
Even with successful sustained antiretroviral therapy (ART)-mediated viral suppression a spectrum of chronic conditions including, cancer, cardiovascular disease, neural disease, hepatic and renal disease continue to pose major health risks.
Protein glycosylation is one of the most common, post-translational modifications and plays a fundamental role in many biological processes and disease pathogenesis including HIV. More recently, microarray technology has been used to analyze the glycome of intact HIV-1 virions. Understanding of the mechanisms of viral evasion as well as modulation of the immune response has also been enhanced by new developments and research in glycomics. At the same time, in the past few years, alterations in glycosylation profile have been reported to be associated with many chronic conditions outside the context of HIV infection. Development of new tools and novel approaches in glycomics has presented opportunities for teams of multi-disciplinary investigators to exploit glycans as possible biomarkers by assessing them in a dynamic range of body fluids. This has led to studies to evaluate these glycans and antibodies to glycans or changes in glycan binding proteins in development of glycomic biomarkers for non-invasive screening and complementary diagnostic tools. Such studies have revealed the potential utility of glycan biomarkers in diseases such as lung cancer, myeloma, neurodegenerative disease, hepatic disease, cardiovascular disease and renal diseases. Some studies have also linked aberrant glycosylation to imparting disease phenotype. However, the relevance of these biomarkers and their potential in screening/diagnosis/risk assessment of similar co-morbidities in the context of HIV has not been fully explored. Additionally, biospecimens from similar disease conditions in HIV and non HIV have not been comparatively profiled. As a result, the discovery and detailed characterization of glycoprotein disease biomarkers in the context of HIV remains an area of potential research.
The scientific objective of this supplement is to stimulate novel areas of research in glycomics of HIV associated co-morbidities by supporting pilot and preliminary investigations. Cross-disciplinary research collaboration is needed between HIV researchers, glycobiologists and other relevant disease researchers to effectively formulate questions and to carry out proposed research in this area. Collaborations between CFAR investigators within the various CFAR working groups such as CNICS and iCHARM and glycobiologists such as investigators that are a part of the consortium for glycomics are encouraged.
Responsive studies could include, but are not limited to the following:
- Research addressing gaps in comparing glycan biomarkers in HIV comorbidities with similar non-HIV comorbidities to assess the impact of underlying HIV
- Serum glycan analysis and glycan profiles for cancers in people with and without HIV
- Discovery of glycan-biomarkers in liver disease in people with and without HIV
- Differences in glycomic profiles in infection associated cancers in people with and without HIV.